prostate cancer | Clinical Trial | Added Jan 28, 2022
Searching for patients with metastatic prostate cancer to test this new treatment combination
This phase 3 trial is examining the effectiveness and safety of niraparib (Zejula) in combination with abiraterone acetate (Zytiga) and prednisone (Deltasone) vs abiraterone acetate and prednisone plus placebo for patients with metastatic prostate cancer. The main outcome to be measured will be the survival time without cancer growing or spreading.
prostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Jan 10, 2022
Comparing the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations.
This study compared the effectiveness of PARP inhibitors for the treatment of patients with BRCA1 and BRCA2 mutations in solid tumors. The data showed that PARP inhibitors could benefit both patients with BRCA1 and BRCA2 mutations with similar effectiveness.
prostate cancer | Medivizor | source: Medivizor | Added Dec 14, 2021
Guest Post: Cancer On Facebook--A Patient's Perspective
Dawn Goo is a waitress, former comedian, breast cancer survivor and is now under treatment for Non Hodgkins Lymphoma. She lives in El Paso, Texas. This is a post from her Facebook page which is gathering momentum in social media among people who have experienced cancer, especially those who areprostate cancer | Research | Treatment | 10 pages | source: Frontiers in oncology | Added Nov 29, 2021
Evaluating the effectiveness of androgen receptor-targeted therapy plus radiotherapy in patients with metastatic castration resistant prostate cancer.
This study evaluated the effectiveness of radiotherapy (RT) plus androgen receptor-targeted therapy (ARTT) on oligo-progressive sites for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that RT on oligo-progressive sites was safe and effective in prolonging treatment with ARTT in patients with mCRPC.
prostate cancer | Medivizor | source: Medivizor | Added Nov 27, 2021
More Free Vacations For Adults With Cancer: Wish Foundations
We are adding to the list of respite opportunities that are available for adults with cancer. In addition to a couple of programs like the ones featured in Free Vacations for Adults affected by Cancer, there are a few foundations for adults with cancer that are much like the well-known Make-A-Wishprostate cancer | Medivizor | source: Medivizor | Added Nov 25, 2021
Infographic on Cancer Immunotherapy
Last summer we provided a series of posts on oncology basics. Oncology Basics: Preparing for ASCO covered some of the history of oncology. In Understanding Cells, we reviewed what is newly understood about cells--it's way beyond what you learned in high school biology. DNA with lots of animated videos also explained someprostate cancer | Medivizor | source: Medivizor | Added Nov 20, 2021
How to Smoothie!
This summer has been a challenge after a family member with celiac disease had a gluten exposure (Click here to read more about celiac disease). Gluten damages the small intestine villi (see 5 Facts You Probably Didn't Know About Your Small Intestines), which are essential for nutrition absorption. For overprostate cancer | Medivizor | source: Medivizor | Added Nov 14, 2021
Quick Guide: Understanding the Importance of the FDA's Keytruda Approval
In July 2015, we published a post called Patients Included In Research: Studying Cancer by Mutation Not Organ. In that post, we shared the goal that cancers would be treated not by the site of origin, but rather by their genetic features. Achieving this goal is closer than you think!prostate cancer | Research | Treatment | 10 pages | source: Journal of clinical oncology | Added Nov 11, 2021
Survival benefit when adding radiation therapy to hormone therapy for metastatic prostate cancer
The aim of this study was to examine the benefit of adding radiation therapy to androgen deprivation therapy (ADT) for metastatic prostate cancer. Researchers reported a significant survival advantage when radiation therapy was combined with ADT.
prostate cancer | Research | Treatment | 10 pages | source: The Lancet. Oncology | Added Nov 07, 2021
Evaluating the effectiveness and safety of apalutamide plus abiraterone and prednisone for the treatment of patients with metastatic castration-resistant prostate cancer.
This study evaluated the effectiveness and safety of apalutamide (Erleada) in combination with abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that apalutamide plus AAP combination significantly improved survival without progression or cancer worsening in these patients.
